Clinical research and evidence
Aciclovir is one of the most extensively studied antiviral medicines for herpesvirus infections. Laboratory studies established its potent activity against herpes simplex and Varicella-zoster viruses, while subsequent clinical trials demonstrated its effectiveness in serious HSV and VZV infections.
Randomized clinical studies of intravenous aciclovir demonstrated important benefits in severe herpesvirus infections, including infections occurring in immunocompromised patients. Intravenous aciclovir also became the standard antiviral treatment for herpes simplex encephalitis and substantially improved outcomes compared with historical treatment approaches.
Clinical studies in herpes zoster demonstrated that aciclovir treatment can shorten the duration of viral shedding, accelerate the cessation of new lesion formation, and promote healing of skin lesions. The clinical benefit is generally greatest when antiviral therapy is started early.
Renal function is particularly important during intravenous treatment because aciclovir is predominantly eliminated by the kidneys. Patients with impaired renal function may therefore require dosage adjustment and careful hydration to reduce the risk of drug accumulation and kidney toxicity.
Intravenous aciclovir is used to treat severe infections caused by herpes simplex virus, including serious primary or recurrent herpes infections in immunocompromised patients. It is also used for severe infections caused by Varicella-zoster virus, including severe chickenpox and herpes zoster, according to the clinical circumstances.
For herpes simplex encephalitis, intravenous aciclovir is a principal antiviral treatment. Its therapeutic effect is based on inhibition of viral DNA polymerase and interruption of viral DNA replication.
The medicine is intended for intravenous administration after reconstitution of the lyophilized powder. The dose, final solution concentration, infusion rate, and treatment duration are determined by the treating physician according to the type and severity of infection, age, body weight, immune status, and renal function. Intravenous aciclovir is generally administered by slow infusion rather than rapid intravenous bolus injection. Adequate hydration should be maintained during treatment, particularly in patients at increased risk of kidney impairment. Preparation and administration must be performed by qualified healthcare professionals.
